Continuous veno venous hemofiltration in treatment of acute necrotizing pancreatitis. 2003

Honglang Xie, and Daxi Ji, and Dehua Gong, and Yun Liu, and Bin Xu, and Hong Zhou, and Zhihong Liu, and Leishi Li, and Weiqin Li, and Zhufu Quan, and Jieshou Li
Research Institute of Nephrology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, China. xiehl_doc0395@sina.com

OBJECTIVE To investigate the effectiveness of using continuous veno venous hemofiltration (CVVH) in the treatment of acute necrotizing pancreatitis (ANP). METHODS Thirteen ANP patients were involved in this study, including 4 females and 9 males, averaging 50.6 +/- 10.8 years old. CT scans upon admission revealed 33% necrosis involving the body of the pancreas in 2 patients, 67% necrosis in 3 patients and 100% necrosis in the other 8; the CT severity score was 8.9 +/- 2.1. CVVH was maintained for at least 72 hours and the AN69 hemofilter (1.2 m(2)) was changed every 24 hours. The ultrafiltration rate during CVVH was 2993.9 +/- 983.0 ml/h, the blood flow rate was 250 - 300 ml/min, and the substitute fluid was infused in a pre-diluted manner. Low molecular weight heparin was used as anticoagulant. RESULTS CVVH was well tolerated in all the patients. Bloody abdominal cavity drainage fluid was observed in 2 patients, but no other side-effects related with CVVH were observed. Two patients died of systemic fungal infections and another died of intracranial fungi infection, resulting in an ICU mortality of 23.1%. Ten of the patients survived in the ICU, but one of them died for other reasons unrelated to the SAP before discharge. The APACHE II score before CVVH was 15.2 +/- 6.5, but decreased significantly to 8.1 +/- 5.3, 7.5 +/- 4.9 and 8.0 +/- 5.2 at the 24th, 48th and 72nd hour after CVVH, respectively (P < 0.01). Serum concentration of IL-1beta and TNFalpha decreased to the trough at the 6th hour after a new hemofilter was used and increased slowly to pre-CVVH levels 12 hours later. After CVVH had ceased, the serum levels of two cytokines increased to their peaks at the 120th hour and decreased eventually at the 144th hour. The sieving coefficient (SC) of IL-1beta and TNFalpha was 0.33 +/- 0.11 and 0.16 +/- 0.08. CONCLUSIONS CVVH offered therapeutic options for ANP and was well tolerated resulting in clearance of IL-1beta and TNFalpha; CVVH at early stages of SAP may contribute to the improvement of outcome.

UI MeSH Term Description Entries
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006440 Hemofiltration Extracorporeal ULTRAFILTRATION technique without HEMODIALYSIS for treatment of fluid overload and electrolyte disturbances affecting renal, cardiac, or pulmonary function. Arteriovenous Hemofiltration,Venovenous Hemofiltration,Arteriovenous Hemofiltrations,Hemofiltration, Arteriovenous,Hemofiltration, Venovenous,Hemofiltrations,Venovenous Hemofiltrations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D019283 Pancreatitis, Acute Necrotizing A severe form of acute INFLAMMATION of the PANCREAS characterized by one or more areas of NECROSIS in the pancreas with varying degree of involvement of the surrounding tissues or organ systems. Massive pancreatic necrosis may lead to DIABETES MELLITUS, and malabsorption. Acute Necrotizing Pancreatitis,Hemorrhagic Necrotic Pancreatitis,Necrotizing Pancreatitis, Acute,Pancreatic Necrosis,Pancreatitis Necrotising,Pancreatitis Necrotizing,Hemorrhagic Necrotic Pancreatitides,Necrosis, Pancreatic,Necrotic Pancreatitis, Hemorrhagic,Pancreatic Necroses,Pancreatitis Necrotisings,Pancreatitis Necrotizings,Pancreatitis, Hemorrhagic Necrotic

Related Publications

Honglang Xie, and Daxi Ji, and Dehua Gong, and Yun Liu, and Bin Xu, and Hong Zhou, and Zhihong Liu, and Leishi Li, and Weiqin Li, and Zhufu Quan, and Jieshou Li
July 2003, Zhonghua nei ke za zhi,
Honglang Xie, and Daxi Ji, and Dehua Gong, and Yun Liu, and Bin Xu, and Hong Zhou, and Zhihong Liu, and Leishi Li, and Weiqin Li, and Zhufu Quan, and Jieshou Li
October 2019, The Cochrane database of systematic reviews,
Honglang Xie, and Daxi Ji, and Dehua Gong, and Yun Liu, and Bin Xu, and Hong Zhou, and Zhihong Liu, and Leishi Li, and Weiqin Li, and Zhufu Quan, and Jieshou Li
April 2019, Experimental and therapeutic medicine,
Honglang Xie, and Daxi Ji, and Dehua Gong, and Yun Liu, and Bin Xu, and Hong Zhou, and Zhihong Liu, and Leishi Li, and Weiqin Li, and Zhufu Quan, and Jieshou Li
December 2006, Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences,
Honglang Xie, and Daxi Ji, and Dehua Gong, and Yun Liu, and Bin Xu, and Hong Zhou, and Zhihong Liu, and Leishi Li, and Weiqin Li, and Zhufu Quan, and Jieshou Li
August 2005, World journal of gastroenterology,
Honglang Xie, and Daxi Ji, and Dehua Gong, and Yun Liu, and Bin Xu, and Hong Zhou, and Zhihong Liu, and Leishi Li, and Weiqin Li, and Zhufu Quan, and Jieshou Li
December 1991, Nihon rinsho. Japanese journal of clinical medicine,
Honglang Xie, and Daxi Ji, and Dehua Gong, and Yun Liu, and Bin Xu, and Hong Zhou, and Zhihong Liu, and Leishi Li, and Weiqin Li, and Zhufu Quan, and Jieshou Li
January 1990, Nephrologie,
Honglang Xie, and Daxi Ji, and Dehua Gong, and Yun Liu, and Bin Xu, and Hong Zhou, and Zhihong Liu, and Leishi Li, and Weiqin Li, and Zhufu Quan, and Jieshou Li
January 2013, Journal of clinical gastroenterology,
Honglang Xie, and Daxi Ji, and Dehua Gong, and Yun Liu, and Bin Xu, and Hong Zhou, and Zhihong Liu, and Leishi Li, and Weiqin Li, and Zhufu Quan, and Jieshou Li
March 1999, Zhonghua wai ke za zhi [Chinese journal of surgery],
Honglang Xie, and Daxi Ji, and Dehua Gong, and Yun Liu, and Bin Xu, and Hong Zhou, and Zhihong Liu, and Leishi Li, and Weiqin Li, and Zhufu Quan, and Jieshou Li
October 2013, Hepato-gastroenterology,
Copied contents to your clipboard!